Elsbernd Brian 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Sep 10, 2025
Insider Transaction Report
Form 4
Elsbernd Brian
Chief Compliance/Legal Officer
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2025-09-08$2.24/sh+112,475$251,944→ 301,039 total - Exercise/Conversion
Options to Purchase Common Stock
2025-09-08−112,475→ 846,609 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (112,475 underlying) - Sale
Common Stock, par value $0.001 per share
2025-09-08$20.30/sh−30,000$609,000→ 271,039 total
Footnotes (3)
- [F1]The shares reported as sold herein and in Table I to the Reporting Person's Form 4 filed with the SEC on September 5, 2025 were sold on the open market to fund the exercise price and tax withholding due from Mr. Elsbernd on the exercise of the 112,475 stock options reported in Table II hereto and the 50,000 stock options reported on Table II to the Reporting Person's Form 8-K filed with the SEC on September 5, 2025.
- [F2]Represents a weighted average price for the shares sold. Shares were sold in a range from $20.225 to $20.315 per share.
- [F3]Options vested in three annual tranches beginning on December 19, 2019.